[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obese-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obese-adults":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":48},"100620863","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-mb-1-on-metabolic-health-in-overweight-and-obese-adults-100620863",false,"NCT07363148","A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","Inclusion Criteria:\n\n1. Males \\& females aged 18-50 years, inclusive\n2. BMI of 25.0 to ≤ 34.9 kg\u002Fm²\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically-approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n4. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline as assessed by the QI\n5. Abdominal obesity: Waist circumference of \\> 94 cm (37 inches) in men and \\> 80 cm (31.5 inches) in women\n6. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits\n7. Agrees to maintain current lifestyle habits (diet, medications, supplements, and sleep) as much as possible throughout the study\n8. Provided voluntary, written, informed consent to participate in the study\n9. Healthy as determined by medical history as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of the investigational product or placebo ingredients\n3. Gastric bypass surgery or other surgeries to induce weight loss\n4. Metal implants or other physical characteristics\u002Flimitations that may affect DEXA scan results as assessed by the QI\n5. Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI\n6. Current or history of eating disorders as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n10. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n11. Type I or Type II diabetes\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Self reported confirmation of glaucoma\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n26. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n27. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n28. Individuals who are unable to give informed consent\n29. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","ALL","18 Years","50 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is:\n\nWhat is the difference in change in body weight from baseline at Day 84 between MB-1 and placebo?\n\nParticipants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.",[27,28,29,30,31],"Obese","Overweight Adults","Obese Adults","Body Weight Control","BMI",[33,34,35,36],"Arrae","MB-1","Obesity","Overweight","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":21},"2026-08",{"date":45,"type":21},"2027-01",{"name":33,"class":47},"INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100644244","assessment-of-the-natural-history-and-prognostic-factors-of-therapeutic-response-in-sub-phenotypes-of-patients-with-obesity-the-bolobe-study-100644244","NCT07666425","ASSESSMENT OF THE NATURAL HISTORY AND PROGNOSTIC FACTORS OF THERAPEUTIC RESPONSE IN SUB-PHENOTYPES OF PATIENTS WITH OBESITY: THE BOLOBE STUDY","ASSESSMENT OF THE NATURAL HISTORY AND PROGNOSTIC FACTORS OF THERAPEUTIC RESPONSE IN SUB-PHENOTYPES OF PATIENTS WITH OBESITY: THE BOLOBE STUDY (BOLOgna for OBEsity Follow-up BOLOBE)","BOLOBE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Body mass index (BMI) ≥ 30 kg\u002Fm², or BMI ≥ 25 kg\u002Fm² with at least one cardiometabolic comorbidity\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Obesity secondary to hypothalamic-pituitary disorders\n* Obesity secondary to adrenal disorders\n* Syndromic obesity",{"count":58,"type":21},10000,"OBSERVATIONAL","The study is observational and single-center and involves (i) the establishment of a retrospective and prospective data collection, and (ii) the development of prognostic and predictive models of response to obesity therapies using statistical modeling and machine learning techniques, exclusively for research purposes.\n\nData collection will be carried out for each patient diagnosed with obesity or overweight whose first visit to the center occurred from January 1, 2000 up to the start of the study, as well as for patients accessing the center during the subsequent 5 years, including patients who died or were lost to follow-up.\n\nWith respect to the primary objective, an interim analysis is planned on the retrospective cohort only, once the collection of data already available at study start has been completed for patients with at least 5 years of follow-up.\n\nData related to instrumental and laboratory examinations and therapeutic interventions, including pharmacological treatments and group-based educational and behavioral therapies, conducted in accordance with routine clinical practice and the most recent relevant national and international guidelines, will be extracted from the electronic health records routinely used at the study center.",[29,62],"Overweight , Obesity","RECRUITING","2026-06-19",{"date":66,"type":41},"2026-06-24",{"date":68,"type":41},"2026-05-30",{"date":70,"type":21},"2038-03",{"name":72,"class":73},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":48},"100626754","nutrimood-inflammation-and-depressive-comorbidity-in-obesity-modulation-by-omega-3-polyunsaturated-fatty-acids-status-100626754","NCT07439744","NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status","Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight\u002FObese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation","Inclusion Criteria:\n\n* Major depressive disorder.\n* Antidepressant drug-free.\n\nExclusion Criteria:\n\n* Schizophrenia\n* Mania\n* Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)\n* Obsessive-compulsive disorder\n* Post-traumatic stress disorder\n* Alcohol or drug abuse\u002Fdependence (except for nicotine)\n* Active suicidal ideation\n* Serious medical\u002Fneurological conditions, especially requiring corticosteroid\u002Fnon-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement","54 Years",{"count":83,"type":21},50,[24],"A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g\u002Fday) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \\\u003C 8%) (81), from the Taiwanese cohort. Associations with PLA2\u002FCOX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.",[29,87],"MDD","2026-02-23",{"date":90,"type":41},"2026-02-27",{"date":92,"type":41},"2025-03-01",{"date":94,"type":21},"2027-12",{"name":96,"class":97},"National Science and Technology Council, Taiwan","OTHER_GOV"]